stella
beta
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer — Stella
Recruiting
Back to Pancreatic Cancer trials
Not a traditional drug trial — this study doesn't follow the standard phase structure.
Trial locations
(1 site)
China
Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing
View full record on ClinicalTrials.gov